Basic Trazodone Information

• INN (International Nonproprietary Name): Trazodone
• Brand Names Available In United Kingdom: Desyrel (listed as marketed worldwide); other specific UK brand listings not specified in the provided data.
• ATC Code: N06AX05
• Forms & Dosages: Immediate‑release tablets (50 mg, 100 mg); extended‑release/prolonged‑release tablets (75 mg, 100 mg, 150 mg; labelled retard/CR/XR in some products); oral solution rarely marketed.
• Manufacturers In United Kingdom: Intas Pharma (listed with UK presence); other manufacturers/suppliers (Angelini, Mylan, Gonane Pharma, Global Pharma Tek, Shandong Octagon, TAPI, Fermion) listed as major suppliers but UK manufacture details not specified.
• Registration Status In United Kingdom: Not specified in the provided data. (FDA and EMA approvals for major depressive disorder are noted in the source material.)
• OTC / Rx Classification: Prescription only (Rx) in all markets per the provided information.

Latest Research Highlights (UK & EU 2022–2025)

Clinicians and auditors in the UK and EU have repeatedly signalled two consistent findings about trazodone use between 2022 and 2025.

The first is modest antidepressant efficacy in major depressive disorder, with symptomatic gains similar to older tricyclics and some selective serotonin reuptake inhibitors for patients who have disturbed sleep.

The second is widespread off‑label use for insomnia, especially at low nocturnal doses (commonly 25–100 mg at bedtime).

Regulatory pharmacovigilance reports (EMA / Yellow Card‑style reporting) highlight rare but serious adverse events, notably priapism, hyponatraemia consistent with SIADH and cardiac arrhythmia in susceptible patients.

European comparative effectiveness work shows trazodone achieves symptomatic improvement comparable to older TCAs and some SSRIs for sleep‑disturbed depression, but head‑to‑head superiority is not established.

UK mental health trust audits report frequent early discontinuation due to sedation or orthostatic symptoms, while low abuse potential and affordability remain reasons for steady NHS prescribing.

Key research gaps include few large randomised trials for low‑dose nocturnal use and limited long‑term real‑world safety data in frail older people.

Clinical Effectiveness In The UK

Many NHS prescribers use trazodone for moderate‑to‑severe major depressive disorder and commonly prescribe it off‑label for insomnia when other options fail.

Trust audits and patient‑reported outcome measures indicate improvements in mood and reduced sleep latency, particularly where 5‑HT2 antagonism helps sleep architecture.

Daytime sedation is the leading reason for dose timing adjustments or switches to alternatives in primary care and secondary mental health services.

Clinicians usually review response at two to four weeks and document follow‑up plans in line with NHS practice.

• Benefits: Symptomatic mood improvement; reduced sleep latency; low abuse potential.
• Common Adverse Effects: Sedation, morning grogginess, dizziness, orthostatic symptoms, dry mouth.

Indications And Expanded Uses

Regulatory approvals list trazodone for major depressive disorder as the licensed indication.

In UK clinical practice many prescribers also use trazodone off‑label for insomnia and related sleep disturbance, frequently at low nightly doses.

• Licensed: Major depressive disorder (as per EMA/FDA listings in the source material).
• Common Off‑Label Uses: Insomnia (low bedtime doses 25–100 mg), anxiety with sleep disturbance, adjunctive therapy for partial SSRI response, occasional use when neuropathic pain coexists.

Prescribing Notes

• Use in bipolar disorder requires caution because antidepressants can precipitate mania; co‑prescription of a mood stabiliser is standard practice where indicated.
• Paediatric use is not recommended; safety and efficacy are unestablished in children.
• Always check the local formulary and document informed consent for off‑label prescriptions.

Composition And Brand Landscape

The active substance is trazodone hydrochloride (INN: trazodone).

Multiple international brand names appear in product registers, with Desyrel being listed as marketed worldwide in the source data.

Immediate‑release tablets are commonly available as 50 mg and 100 mg strengths, and extended or prolonged‑release forms are sold as 75 mg, 100 mg and 150 mg in different markets.

In UK supply chains generic trazodone is commonly sourced from wholesalers and manufacturers such as Intas and Mylan, while branded products may be supplied by Angelini and other European firms according to the data provided.

Pharmacists should confirm whether a dispensed product is immediate‑release or extended‑release when making substitutions, because formulation affects sedation and pharmacokinetics.

Contraindications And Special Precautions

Certain situations contra‑indicate trazodone use and others require close monitoring.

Absolute contraindications in the supplied data include known hypersensitivity to trazodone, recent myocardial infarction and acute intoxication with alcohol or other CNS depressants.

Special precautions apply in patients with cardiac disease due to QT prolongation risk, and in severe hepatic or renal impairment where dose accumulation may occur.

Other cautions include angle‑closure glaucoma, seizure disorders, and bipolar disorder because of mania risk.

Elderly patients require lower starting doses and monitoring for orthostatic hypotension and hyponatraemia (SIADH).

Pregnancy and breastfeeding decisions should balance maternal benefit versus limited safety data and involve obstetric psychiatry where appropriate.

Dosage Guidelines

Treatment regimens differ by indication and patient group, and doses should be individualised with slow titration.

Typical starting doses for depression are 75–150 mg per day in divided doses, with outpatient maxima cited up to 400 mg per day and inpatient references up to 600 mg per day.

For off‑label nocturnal insomnia many clinicians use low single nightly doses of 25–100 mg at bedtime.

Elderly patients should start low (for example 25–50 mg at night for sleep) and undergo slower titration with monitoring for falls and hyponatraemia.

Taper slowly when discontinuing to reduce withdrawal symptoms, and advise missed‑dose guidance: take when remembered unless close to the next dose, do not double up.

Interactions Overview

Trazodone interacts with a number of commonly used medicines and substances.

Concomitant serotonergic agents (SSRIs, SNRIs, MAOIs, triptans) increase the risk of serotonin syndrome and need careful review before co‑prescription.

Strong CYP3A4 inhibitors or inducers can alter plasma trazodone levels and require dose adjustments or alternative choices.

Alcohol and other central nervous system depressants potentiate sedation and respiratory depression and should be avoided.

Co‑prescription with QT‑prolonging medicines (some antipsychotics and antiarrhythmics) may require ECG monitoring.

Be alert for serotonin syndrome signs: agitation, hyperreflexia, fever, autonomic instability, and altered mental state, and treat as an emergency if suspected.

Cultural Perceptions And Patient Habits

On UK patient forums trazodone commonly appears as a “sedating antidepressant” recommended when sleep problems are prominent.

Community pharmacists are widely trusted and often advise about bedtime dosing to reduce daytime grogginess and fall risk.

NHS 111 and local trust helplines provide triage for adverse events, and electronic prescriptions help pharmacists follow up with patients quickly.

• Patient Perceptions: Useful for sleep; concern about morning grogginess; stigma around “antidepressant for sleep”.
• Forum Themes: Reports of improved sleep at low nightly doses; variable daytime sedation; calls for CBT‑I before long‑term medication.
• Pharmacist Counselling Points: Confirm indication, advise on dose timing, warn against alcohol and driving, and arrange follow‑up.

Clinicians should document counselling about off‑label use and set clear review dates, particularly for older adults at risk of falls.

Availability And Pricing Patterns

Trazodone is prescription‑only across the UK and is stocked by major chains and independent pharmacies, with growing online and e‑prescription channels supplying NHS and private patients.

In England NHS prescriptions attract the standard charge unless the patient is exempt, while prescriptions are generally free in Scotland, Wales and Northern Ireland.

Generic trazodone formulations keep private prices low, while branded extended‑release products tend to cost more.

Regional formularies may favour particular generics because of procurement contracts with suppliers such as Intas, Mylan or Angelini as noted in the supplied data.

Occasional supply issues affect specific strengths or ER forms; pharmacies may substitute based on local policy and availability.

In our online pharmacy, trazodone is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Typical private cost ranges vary by formulation and strength, with generics markedly cheaper than branded ER products; exact prices depend on retailer and region.

Comparable Medicines And Prescribing Preferences

When choosing an antidepressant in NHS practice clinicians weigh comorbidity, cardiac profile and prior response as well as side‑effect tolerance.

Common alternatives include SSRIs such as sertraline and escitalopram for depression, and mirtazapine or doxepin when sedative benefit is required.

• GP Decision‑Support: Consider trazodone when insomnia is a dominant symptom and alternatives have failed, but discuss off‑label status and plan a short trial with review dates.
• Prefer psychological treatments (CBT‑I) first for chronic insomnia and reserve pharmacotherapy for short‑term use supported by monitoring.

FAQ

• Will trazodone help my sleep?

  Many patients report reduced time to fall asleep at low nightly doses (25–100 mg), but UK guidance recommends CBT‑I first and a shared decision on off‑label use with your GP.

• Is it safe with my other medicines?

  Interactions are important to check, especially with SSRIs, MAOIs, QT‑prolonging drugs and alcohol; ask your pharmacist or GP to review all medicines and vaccines.

• What are the serious risks?

  Rare but urgent risks include priapism (seek immediate care), severe hyponatraemia and serotonin syndrome; elderly patients need monitoring for falls and electrolyte problems.

• How long will I need it?

  For depression continue treatment for at least six months after remission; for insomnia aim for short courses with clear review dates and follow‑up.

Guidelines For Proper Use

Pharmacists and prescribers should follow a structured counselling and monitoring approach when trazodone is supplied.

Confirm the indication (licensed depression vs off‑label insomnia), formulation (IR vs ER) and strength before dispensing.

Review concomitant medicines for serotonin syndrome risk and CYP3A4 interactions.

• Advise dose timing, usually at bedtime if sedating, and warn about driving and alcohol.
• Arrange follow‑up within two to six weeks for off‑label insomnia prescriptions and within two to four weeks for depression initial review.
• Provide written taper plans and counsel on gradual withdrawal to avoid discontinuation effects.

Direct patients to NHS.uk medicine pages and the Yellow Card scheme for adverse event reporting, and refer promptly to urgent care for symptoms such as priapism or signs of serotonin syndrome.

Delivery Across United Kingdom